AI Governance
AI change control should begin before the first model update
A practical framework for connecting intended use, model changes, performance evidence, risk, and release decisions.
Read analysis
9 min read
Regulatory intelligence for the product lifecycle
Understand what changed. Know what to do next.
Clear, practical analysis for teams developing medical devices, drugs, biologics, advanced therapies, combination products, and AI-enabled healthcare technologies.
Latest intelligence
Analysis for consequential decisions
9 analyses
Combination Products
One product record for drug-device combination development
Why constituent-part teams need a shared evidence model - not parallel document libraries.
Read analysis
8 min read
Medical Devices
QMSR readiness is an evidence problem - not a checklist problem
How to convert procedural mapping into demonstrable control across the quality system.
Read analysis
7 min read
Pharma
CMC change impact: finding the hidden regulatory dependencies
A structured approach to assess how one manufacturing change propagates across evidence, dossiers, commitments, and markets.
Read analysis
10 min read
Biologics
Potency strategy as a lifecycle system
Linking mechanism of action, critical quality attributes, assays, acceptance criteria, and manufacturing evolution.
Read analysis
9 min read
Cell & Gene Therapy
Traceability in advanced therapies: from starting material to patient
Designing chain-of-identity, chain-of-custody, manufacturing, and evidence controls as one connected system.
Read analysis
11 min read
Combination Products
Global pathway comparison without false equivalence
How to compare the United States, European Union, and Japan while preserving jurisdiction-specific logic.
Read analysis
8 min read
AI Governance
Source-linked regulatory drafting: what validation should mean
Citations are necessary, but reliable regulatory drafting also requires scope, context, review, and controlled approval.
Read analysis
6 min read
Medical Devices
Submission readiness: measure evidence, not document count
A dossier can contain every expected filename and still be unready for review.
Read analysis
7 min read
Featured analysis
The regulatory evidence graph: beyond document management
Field note · 8 min
RequirementRiskTestSubmissionChangeProductclaimEvidence relationship
A connected evidence model can reveal gaps, accelerate change assessment, and make regulatory conclusions reviewable.
- Connect claims to requirements, risks, controls, and tests.
- Expose gaps before a reviewer does.
- Assess change impact across products and markets.
EE
eeRegOS Editorial Team
Regulatory Strategy & Intelligence
The eeRegOS editorial standard
From regulatory signal to accountable action.
Every article helps teams move from awareness to an evidence-based decision - without confusing AI-generated assistance with regulatory approval.
- 01SignalWhat changed or deserves attention?
- 02ContextWhere does it apply - and where does it not?
- 03ImpactWhich products, evidence, and teams are affected?
- 04ActionWhat should be reviewed, documented, or escalated?
The eeRegOS briefing
Regulatory change, distilled.
A concise monthly briefing covering meaningful developments across product categories and major markets. No noise - only changes that may affect strategy, evidence, or execution.
About eeRegOS
AI-powered regulatory intelligence, guided by human expertise.
eeRegOS connects regulatory strategy, product evidence, quality, submissions, and lifecycle change across medical devices, pharmaceuticals, biologics, cell and gene therapies, and combination products.
Its specialized copilots operate with curated sources, dedicated retrieval domains, validation controls, and traceable source records within one secure infrastructure.
Explore the platformContent is educational and does not constitute legal or regulatory advice. Product-specific decisions should be reviewed by qualified professionals using current authoritative sources.